scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Generated net FUROSCIX revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of$ 40.8 million as of June 30, 2025 "We're very pleased with the continued momentum behind FUROSCIX, with net revenue of $16 millio ...